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ABSTRACT  
Objective: To examine the performance of the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status/quality of life 
(QoL) scale and two summary scores to detect changes in the QoL profile over time, according to 
changes in the individual scales.  
Study Design and Setting: Data came from 167 clinical trial patients with unresectable (advanced) 
hepatocellular carcinoma. The global health status/QoL scale of the questionnaire contained two 
items: overall health and overall QoL. Nordin and Hinz proposed summary scores for the 
questionnaire. A mixed effect model was fitted to estimate trends in scores over time.  
Results: Predominantly the individual scale scores declined over time, however the global health 
status/QoL score was stable (rate of change=-0.3 per month, 95% CI: -1.2, 0.6). Nordin’s summary 
score, which gave equal weight to the 15 questionnaire scales and Hinz’s summary score,  which 
gave equal weight to the 30 questionnaire items, showed a statistically significant decline over time, 
3.4 (95% CI: -4.5, -2.4) and 4.2 (95% CI: -5.3, -3.0) points per month, respectively. 
Conclusion: In contrast to the global health status/QoL scale the summary scores proposed by 
Nordin and Hinz detected changes in subjects’ QoL profile described by the EORTC QLQ-C30 
individual scales.  
Keywords: EORTC QLQ-C30; cancer; advanced hepatocellular carcinoma; response shift; quality of 
life; scoring procedure 
Running title: Summary measures for the EORTC QLQ-C30 
Word count:  4560  
ClinicalTrials.gov number: NCT00041275 
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What is new? 
Key findings 
- Cross-sectionally, the global health status/QoL scale did not have strong correlation with the 
functioning, symptom and finance scales of the EORTC QLQ-C30. 
- Longitudinally, the global health status/quality of life scale disagreed with the majority of the 
functioning and symptom scales of the EORTC QLQ-C30. 
- Nordin’s and Hinz’s summary scales summarised the changes in overall QoL profile according 
to changes in functioning and symptom scales in terms of showing a clinically and statistically 
significant decline.  
- The summary scores based on the sum of individual items/scales had better agreement, both 
cross-sectionally and longitudinally, with the QoL profile captured by the EORTC QLQ-C30 
individual scales than the global health status/quality of life scale. 
What this adds to what is known? 
- Our findings support the concerns raised about use of the global QoL scale as the overall QoL 
measure; and support the theory that the global QoL scale is more subject to response shift, 
whereas the scales based on specific items are less subject to these influences. 
 
What is the implication and what should change now? 
- Non-specific, global items to measure overall QoL profile captured by the EORTC QLQ-C30, 
especially longitudinally should be used with caution. 
- Nordin’s summary score and Hinz’s summary score have potential to serve as an overall QoL 
measure that summarises the profile captured by the EORTC QLQ-C30 individual scales. 
- QoL rated by a global rating continue to remain relevant when one wishes to capture patients’ 
perceptions about their overall level of QoL. 
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1. INTRODUCTION 
The preservation of quality of life (QoL) is an important goal in the management of cancer, particularly 
when the treatment is given with palliative intent or has a high level of toxicity [1, 2]. QoL instruments 
measure patients' own perceptions of their well-being in various areas such as physical, 
psychological, social, financial, and somatic [3, 4]. An important characteristic of a QoL instrument is 
that it can detect changes in well-being of multiple dimensions and hence overall QoL [5]. However, 
assessing change in overall QoL using a multi-dimensional QoL instrument is challenging as 
individual dimensions may change in different directions. A summary measure indicating aggregate 
status of a multi-dimensional QoL profile is desired to evaluate the change in overall QoL over time. 
This is particularly important in clinical trials, which are often expected to pre-specify a primary end-
point.   
The EORTC QLQ-C30 is a widely-used instrument for measuring QoL in patients with cancer 
[3]. The results of a recent systematic review found it to be reliable and recommended it for use in 
both clinical trials and clinical practice [6]. The QLQ-C30 includes 30 items for 15 dimensions/scales: 
5 functional scales (physical, role, cognitive, social and emotional functioning), 3 symptom scales 
(fatigue, nausea/vomiting and pain), 5 single-item symptom scales (dyspnoea, sleep disturbances, 
appetite loss, constipation, and diarrhoea), a single-item scale for the perceived financial impact of the 
disease and treatment, and a global health status/QoL scale comprised of two items (global QoL 
scale for brevity). The two items of the global QoL scale rate a patient’s overall health and overall QoL 
[7]. The EORTC does not recommend any overall summary of all the item/scale scores. Instead, it 
suggests using the global QoL scale as the overall summary measure for QoL [7].  
Global ratings for QoL are useful in allowing patients to express their own perceptions of the 
concept; however they can be too simplistic [8]. Concerns about using the 2-item based global QoL 
scale as the overall QoL measure have been raised by various researchers [9-11]. There are two 
conceptual issues. Firstly, the use of only two items and ignoring the other 28 items in the QLQ-C30 
to characterize overall QoL may lead to loss of precision [12]. Secondly, it is possible that the global 
QoL scale indicates a better outcome (or worse outcome) whilst the majority of the individual scales 
indicate worse outcomes (or better outcomes). This would lead to difficulty in interpretation and 
making conclusions. In particular, Hinz et al. hypothesized that the global QoL scale may be more 
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affected by the ‘response shift’ phenomenon than the specific scales, possibly leading to seemingly 
different trajectories over time [11]. Concerns have also been raised regarding the statistical efficiency 
of the QLQ-C30 global scale to detect change over time [14]. Hence, there have been suggestions, 
and counter-arguments, about fully utilizing all 30 items to generate a summary score for overall QoL 
[9-11, 13].  
Nordin et al. suggested a summary score based on the sum of all scales of the QLQ-C30, 
except the scale for financial problems [9]. Hinz et al. suggested a summary score based on the sum 
of all items of the QLQ-C30 [11]. Gundy et al. proposed a two-factor model, one for physical and one 
for mental health, as a basis for deriving summary scores [15]. However, Gundy et al. have not yet 
proposed an algorithm for deriving summary scores. Nevertheless, no methods for deriving an overall 
summary score have been endorsed by the EORTC nor is there a consensus among researchers.  
Hepatocellular carcinoma (HCC) is expected to affect physical functioning, role functioning, 
symptoms of fatigue, pain, dyspnea, insomnia, and appetite loss [16].  Patients with unresectable 
HCC have limited life expectancy, which is associated with poor functional status and distress due to 
symptoms [17, 18]. Drawing on data from a longitudinal multi-centre clinical study in unresectable 
(advanced) HCC patients, this paper aimed to examine the performance of the global QoL scale, 
Nordin’s summary score and Hinz’s summary score in relation to the individual scales of the QLQ-C30 
and in relation to time. We examined whether (i) the baseline score of the global QoL scale and the 
summary scores of Nordin’s and Hinz’s were at least moderately correlated with the baseline scores 
of the functional, symptom and finance scales of the QLQ-C30, (ii) the rates of change in the global 
QoL scale and the two summary scores were at least moderately correlated with the rates of change 
in the functional, symptom and finance scales in a longitudinal setting, and (iii) the global QoL scale 
and the two summary scores declined over time in a degree similar to the majority of the functional, 
symptom and finance scales.  
2. METHODS 
2.1. Design and assessments 
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Data was drawn from a multi-centre randomized controlled double-blind study that recruited 
patients between February 2002 and November 2006. The study aim was to compare efficacy and 
safety of megestrol acetate with placebo in patients with unresectable HCC. The primary trial end-
point was overall survival and the key secondary end-points were safety and QoL. The trial analysis 
found no clinically meaningful effect of study treatment on overall survival or the global QoL scale as 
measured by the QLQ-C30 [17]. Hence this analysis combined the treatment and placebo groups.   
Patients were recruited from 7 centres from 6 Asia-Pacific nations: Singapore, Myanmar, New 
Zealand, Philippines, South Korea and Vietnam. Details of the trial protocol and findings have been 
reported previously [17]. Patients were randomized (allocation ratio of 1:2) to either placebo or 
megestrol acetate 320 mg/day for 12 months, in addition to best supportive care. Baseline and 
monthly assessments included a QoL assessment using the QLQ-C30. In Singapore, where 
multilingualism is common, participants chose to use the English or Chinese version of the 
questionnaire. Participants in Vietnam, South Korea and Myanmar used the Vietnamese, Korean and 
Burmese versions, respectively. In New Zealand and the Philippines, the English versions were used. 
Before the clinical examination of the visits, patients were asked to fill in the QLQ-C30 questionnaire if 
they were literate. Otherwise a research coordinator administered the interview. The option of 
interviewer administration was allowed as per the QLQ-C30 administration guidelines [19]. The 
protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by 
the Institutional Review Boards of the participating institutions. Written informed consent was obtained 
before enrolment. 
2.2. Scoring algorithms 
The QLQ-C30 functional, symptom and finance scale items are scored on a 4-point scale. 
These 4 levels include: “Not at all”, “A little”, “Quite a bit” and “Very much”. For the present study 
symptom items and scales were recoded so that a higher score indicated reduced symptomology. 
Therefore, all items and scales were coded so that a higher score indicated lower outcomes i.e. 
higher scores indicated a healthier level of functioning or better QoL or lower 
symptomology/problems. The raw scores (mean of item-level scores) of the scales were transformed 
to scores that ranged from 0-100 [9]. In the case of missing items if at least half of the items from a 
scale had been answered then the missing value was replaced with the mean of the items that were 
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completed, otherwise the scale score was set to missing. For single item measures, the scale score 
was set to missing if the item was not answered [7]. Patients that had a score for each of the QLQ-
C30 scales/items at baseline were included in the analyses. 
The global QoL scale: The global QoL scale is comprised of 2 items which are scored from 1 to 
7 with a score of 1 representing “very poor” and 7 indicating “excellent”. Similar to the functional and 
symptom scales, the mean of two item-level scores was transformed to a score that ranged from 0-
100 and a higher score indicated a better QoL.  
Nordin’s summary score: Nordin et al. suggested a summary score based on the sum of scales 
except the scale regarding financial problems [9].  However we deemed the financial scale to be of 
value in our setting so we included it. The summary score was calculated by summing the 
transformed scores of all the 15 scales (including the global QoL scale), and then further transformed 
to the 0-100 scale. Nordin et al. proposed that missing values were handled as per the EORTC 
manual [7]. Therefore in the case of missing items, the value was replaced with the mean of the 
remaining items of the corresponding scale when at least 50% of the scale was answered.  If any of 
the items remained missing and hence the corresponding scale was missing, the summary score was 
set to missing. 
Hinz’s summary score: Hinz et al. suggested a summary score as the mean value of all 30 
items [11]. It was calculated by first transforming all the item-level scores to the 0-100 range. The 
summary score was then calculated as the mean of the transformed item-level scores (including the 
items on the global QoL scale). In the case of missing items, the value was replaced with the mean of 
the remaining items of the corresponding QLQ-C30 scale when at least 50% of the scale was 
answered [6]. If any of the items remained missing the summary score was set to missing. 
2.3. Statistical analysis 
The relationship between the global QoL scale and the score of each of the functional, 
symptom and finance scales at baseline was examined using the Spearman’s correlation coefficient 
(ρ). The baseline global QoL scale was expected to at least moderately correlate with the baseline 
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score of each functional/symptom/finance scale. Correlations of between 0.4 and 0.59 were deemed 
moderate and correlations higher than or equal to 0.6 were deemed strong [20]. 
The number of repeated QoL assessments per patient varied substantially due to poor 
survival in this patient group (median survival 2 months; 12-month survival rate 3%). The mixed effect 
model is robust and fully utilizes all available data including those who have only one measurement, 
therefore it is suitable for the assessment of trajectories in the presence of incomplete observations 
[21, 22]. A mixed effects model for the global QoL scale and each of the functional/symptom/finance 
scales was fitted to estimate the trends over time. It was expected that the global QoL scale and the 
specific scales would show a trend to decrease over time in this study population. The model was of 
the form: 
yij = (b0 + β0i) + (b1 + β1i) monthij + eij 
where b0 and b1 indicate the group’s mean level of QoL at baseline and rate of change in mean QoL 
per month, β0i and β1i  indicate the ith patient’s deviation from the intercept and slope, respectively, as 
compared to the group average. They are known as random intercepts and random slopes in mixed 
models. β0i and β1i were assumed to be normally distributed with mean 0 and variance to be estimated 
and were allowed to be correlated.  
The individual random intercept and slope (rate of change) for each patient were calculated 
using the Best Linear Unbiased Predictor (BLUP) [21, 22].  The relationship between the individual 
estimates of the slope for the global QoL scale and individual estimates of the slope for the specific 
scales were examined using the Spearman’s correlation coefficient (ρ). It was expected that the 
individual rate of change in the global QoL scale would be at least moderately correlated with the 
individual changes in each of the specific scales. 
Nordin’s summary score and Hinz’s summary score were analyzed similar to the global QoL scale. In 
addition we ran a sensitivity analysis to examine the extent the correlation coefficients between the 
specific scales/items and the summary scores were inflated due to the scales and items already being 
included in the summary scores.  We examined this possibility by calculating the correlation 
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coefficients between scales/items and summary scores excluding any common items from the 
summary scores. 
3. RESULTS 
3.1 Descriptive summary 
A total of 167 patients (90.3% of the trial participants) completed the QLQ-C30 at baseline 
and were included in the analysis. Median number of QLQ-C30 questionnaires completed per patient 
was 3 (25th percentile 2 and 75th percentile 4). 
Table 1 shows the demographic and clinical characteristics of the patients at baseline. 
Median age was 56.1 years (range 20.1 to 80.9 years). The majority of patents were male (86.2%) 
and most were recruited from centres in Myanmar (29.9%), Singapore (22.2%) and Vietnam (22.2%). 
The majority of the participants were experiencing symptoms that affected daily functioning: 85.6% 
were of grade 1 or above on the Eastern Cooperative Oncology Group (ECOG) performance status. 
Table 2 shows the summary scores of the EORTC global QoL, summary scores and 
functional/symptom/finance scales at baseline. Mean scores across both summary scores and scales 
were towards the upper end of the scale indicating a higher level of QoL and a higher level of 
functioning and lower level of symptomology. The global QoL score sat in the centre of the scale. 
3.2 Correlation with functional/symptom/finance scales 
Table 3 shows the correlation coefficients between the global QoL scale, Nordin’s summary 
score, Hinz’s summary score and each of the specific scales of QLQ-C30 at baseline. The global QoL 
scale showed moderate, positive correlation with physical functioning, role functioning, fatigue, pain 
and appetite loss symptom scales (a higher score meant better outcome for all scales; each ρ≥0.4, 
each p-value<0.05). Nordin’s summary score showed moderate-to-strong, positive correlation with all 
of the functional scales and symptom scales (each ρ≥0.4, each p-value<0.05), except weak 
correlation with constipation and diarrhoea symptom scales. Similar results were observed for the 
correlation between Hinz’s summary score and functional/symptom scales at baseline as just 
described for Nordin’s summary score.   
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Table 4 shows the correlation coefficients between the individual random slope (rate of 
change over time) for the global QoL scale, Nordin’s summary score, Hinz’s summary score and the 
corresponding individual random slope for each of the specific scales, obtained from the mixed effects 
model. Over time the global QoL scale positively and moderately correlated with the physical 
functioning, emotional functioning and fatigue symptom scales (each ρ≥0.4, p-value<0.01), and 
negatively and moderately correlated with the diarrhoea symptom scale (ρ=-0.4, p-value<0.01). The 
rate of change of Nordin’s summary score showed moderate-to-strong, positive correlation with 
physical, emotional, cognitive functioning scales and fatigue, dyspnoea, insomnia symptom scales 
(each ρ≥0.4, p-value<0.01). There was moderate-to-strong, negative correlation with the pain, 
appetite loss and diarrhoea symptom scales (each ρ≤-0.4, p-value<0.01).  Similar results were 
observed for correlation between the rate of change in Hinz’s summary score and that for the specific 
scales as just described for Nordin’s summary score.   
Calculating the correlation coefficients between scales/items and summary scores, excluding 
any common items from the summary scores, gave systematically lower correlations compared to the 
main findings but not dramatically so (supplementary tables 1 and 2). 
3.3 Trajectory over time 
The physical, role and emotional functioning scales and the fatigue, dyspnoea and insomnia 
symptom scales all showed a statistically significant decline over time (Figure 1). In particular, the 
mean physical functioning scale score declined by 7.7 points per month (95% CI: -9.6 to -5.8). 
Conversely the appetite loss and diarrhoea symptom scales both showed a trend to increase over 
time. Despite statistical non-significance, four of the remaining six scales showed a decline over time. 
Despite the decline in most of the specific scale scores, the global QoL score was stable over time 
(b1=-0.3; 95% CI: -1.2 to 0.6). In contrast, Nordin’s and Hinz’s summary score showed a statistically 
significantly decline over time, by 3.4 points (95% CI: -4.5 to -2.4) and 4.2 points (95% CI: -5.3 to -3.0) 
per month respectively.  
4. DISCUSSION 
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We examined the performance of three different overall QoL measures, namely the global 
QoL scale, Nordin’s summary score and Hinz’s summary score, for QLQ-C30 in unresectable 
treatment-naïve advanced HCC patients from Asia-Pacific countries.  
Our findings showed that the global QoL scale performed in an unexpected way longitudinally 
and, to a lesser extent, cross-sectionally. Cross-sectionally, at baseline, the global QoL scale had 
positive, moderate correlation with only physical and role functioning and fatigue, pain and appetite 
symptom scales. In contrast, not surprisingly, the Nordin’s and Hinz’s summary scores showed strong 
correlation with all the functioning scales and moderate-to-strong correlation with most of the 
symptom scales at baseline. Sensitivity analyses suggested the robustness of these findings. 
Longitudinally, although  most of the functioning and symptom scales, including two of the only five 
scales that showed moderate correlation with the global QoL scale at baseline, were declining during 
the study period, the global QoL scale was stable over time (rate of change=-0.3 per month; p-
value=0.48).  In contrast, the Nordin’s and Hinz’s summary scales did summarize the overall profile of 
change in terms of showing a clinically and statistically significant decline.  
A stable trajectory for the global QoL scale during the follow-up, even though the majority of 
functional and symptom scales were showing declines in QoL domains, may have several potential 
explanations. Firstly, it is theoretically possible that global QoL covered more domains than the 
present set of functioning and symptom scales did, and these unobserved domains tended to improve 
over time in this patient group. However, we find it difficult to accept this explanation, given the broad 
coverage of the QLQ-C30 although the QLQ-C30 was not specifically developed for patients with 
terminal diseases. Secondly, there might be a subset of patients who see their overall QoL and/or 
health as always good, perhaps reflecting dispositional optimism [23]. Or some patients might have 
adapted to their disease. That is, patients’ internal standard (e.g., priorities and expectations) changed 
and they may view their QoL differently over time, a phenomenon referred to as ‘response shift’ [24]. 
In the present context, as patients approached the final stage of disease, they might have reached the 
‘acceptance’ stage of psychological response [25]. The two items of the global QoL scale of the QLQ-
C30 were more abstract than the specific scales in the questionnaire [11]. The findings are consistent 
with the hypothesis made by Hinz et al. that the global QoL scale is more subject to response shift 
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(and/or dispositional optimism), whereas the scales based on more concrete and specific items were 
less subject to these influences [11].  
The use of non-specific, global items to measure quality of life is common in clinical research. 
Some of them are part of a more comprehensive questionnaire, e.g. the global QoL items in the QLQ-
C30. Some of them are standalone measures, e.g. the QoL Uniscale [26]. The present findings put 
forwards a cautionary note to the use of such items when one wishes to summarise the overall QoL 
profile captured by the EORTC QLQ-C30, especially in longitudinal settings. 
Although the majority of QoL domains declined in this patient group, the pain symptom score 
was stable over time and the appetite loss symptom score showed statistically significant 
improvement during the follow-up. Severe pain is not a common feature of advanced HCC (unless 
there are bone metastases, which are uncommon).  The terminal stages are characterized by liver 
failure: ascites, jaundice and encephalopathy (comatose).    Another possible explanation is that the 
patients might have been on opioid analgesic for managing their severe pain before and during the 
study [16]. Pharmacologically, randomized controlled trials have demonstrated that megestrol acetate 
significantly improves appetite [17, 27]. Nearly two-thirds of the patients in our study were treated with 
megestrol acetate, which may be a reason for improved appetite loss during the study. The use of an 
overall summary (or a global QoL scale) alone may miss such specific insights. Nevertheless, we 
consider this a reason to use specific scales in addition to, not instead of, an overall summary 
measure. This is especially important in clinical trials that require pre-specification of a primary end-
point and when the intervention is hypothesized to have benefits to multiple aspects of QoL.    
Our study showed that both Nordin’s summary score and Hinz’s summary score have the 
potential to serve as an overall QoL measure that summarizes the profile captured by the QLQ-C30 
individual scales. Both of them had moderate to strong correlation in the expected direction with the 
majority of functional and symptom scales associated with HCC [16]. Both of them were consistent 
with the majority of the functioning and symptom scales in showing a downward QoL trajectory. 
Despite similar findings about the performance of Nordin’s and Hinz’s summary scores, there is a 
formal difference between them. Nordin’s summary score gives equal weight to each 
functional/symptom scale, whereas Hinz’s summary score gives equal weight to each item of the 
QLQ-C30. That is, Hinz’s summary score assigns weights to the scales in proportion to the number of 
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items in the scale. Thus, the physical functioning scale (5 items) has the highest weight, followed by 
emotional functioning scale (4 items), and so on. As such, the Hinz’s scale showed a larger decline 
over time in QoL in this study than the Nordin’s scale. Neither of the two weighting methods is perfect 
in all situations. Ideally, each patient’s weights should be decided by the patient depending on his/her 
preference to different aspects of QoL and hence they can vary from patient to patient. However, 
deciding the preference based weights is a complex procedure. Various methods have been 
discussed in the literature with their merits and demerits and the difficulties involved [28]. In contrast, 
Nordin’s summary score and Hinz’s summary score are simple, sufficiently reliable and valid and 
likely to be useful for many practical purposes.  
  A limitation of this study was that it had a high ‘drop-out’ rate and therefore the data was 
dominated by short-term rather than long-term changes. The high drop-out rate was due to 
unresectable HCC patients having median life expectancy of less than 3 months [17, 29]. We used a 
mixed model approach, to assess the rate of change in the QLQ-C-30 scales over time, which is 
robust and accommodates missing data.  
Another limitation was that the patients were from a clinical trial with strict inclusion criteria, 
which limits the ability to generalize the results to all patients with advanced HCC. Additionally, the 
questionnaire we used was not developed specifically for terminal disease patients. Further studies of 
patients with terminal disease should ideally include measurements of QoL concerns specific to this 
disease stage. The present findings also need replications in patients with non-terminal diseases.    
Last but not least, the two item global scale and a summary score of the remaining items are 
not conceptually comparable [11]. However, the empirical comparison and subsequent discrepancy 
identified are of scientific value.  
In a research setting with no pre-specified interest in a specific QoL component, an overall 
QoL measure is helpful. Firstly, overall QoL scores help avoid multiple comparisons and maintain the 
type 1 error without impacting the sample size. Secondly, an overall score is more useful in facilitating 
clinical decision making than multiple scales that may be in conflict with each other. For example, 
regarding the use or non-use of an intervention. 
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For practical purposes, when an overall score is suitable one can use these findings to 
choose between the global score and the summary scores, dependent on the specific aim of the 
question. In our opinion, when one wishes to obtain a single summary that reflects the overall QoL 
profile captured by the EORTC QLQ-C30 individual scales, the summary scores are more 
appropriate. The summary scores are also recommended when one wishes to detect changes within 
a group or between two groups [14]. However when one wishes to capture the individual patients’ 
perceptions about their QoL then the global score is useful [8]. 
Longitudinally, the rate of change in the global QoL scale and Nordin’s and Hinz’s summary 
measures showed moderate level of negative correlation with some symptom scales, including 
diarrhoea, pain and appetite loss. We do not understand why this is so. We observed that these 
symptom scales either showed an improvement over time or no change over time during the study 
period. It appears that, in this study population, these symptom scales have some unexpected and 
unexplained characteristics. This deserves further investigation. From a methodological point of view, 
this study also highlights issues about the examination of validity and responsiveness to change. In 
this study, the rate of change (i.e. the slope of individual trajectory) of the global QoL scale had 
positive correlation with the rates of change of the physical functioning (0.52) and fatigue (0.54) 
scales. It might be tempting, but incorrect, to think that this implies the measures would show similar 
trends over time. While the physical functioning and fatigue scale scores declined by about 8 and 3 
points per month, the global QoL scale was almost constant over time. The positive correlations only 
indicate that, within the sample, those who had below (above) average of change in physical 
functioning and fatigue scores also had below (above) average of change in global QoL scores. The 
positive correlations do not guarantee that, at the level of the sample as a whole group, the global 
QoL score would change according to changes in the specific scales.     
In conclusion, cross-sectionally, the global QoL scale of QLQ-C30 did not have strong 
correlation with the functioning and symptom scales in patients with unresectable hepatocellular 
carcinoma. Longitudinally, it disagreed with the majority of the functioning and symptom scales in 
showing changes over time. The overall summary scores proposed by Nordin et al. and Hinz et al. 
were better at detecting changes in the profile of QoL captured by the QLQ-C30 individual scales than 
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the global QoL scale. The choice between the global scale and the summary scores ultimately comes 
down to the question of interest. 
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TABLES 
Table 1: Demographic and baseline disease characteristics  
Table 2: Descriptive summaries for the global QoL, summary scores and functional/symptom/finance 
scales of EORTC QLQ-C30 
Table 3: Spearman’s correlations between baseline global QoL scale and summary scores and 
functional/symptom/finance scales of QLQ-C30 
Table 4: Spearman’s correlation between individual rates of change for the global QoL and summary 
scores and the individual rates of change for function/symptom/finance scales of QLQ-C30 
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FIGURES 
Figure 1: Rate of change per month (random slope from mixed effects models) for each QLQ-C30 
functional, symptom and finance scale, the global QoL scale and summary measures 
